Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer,
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported
Quick Look: Staar Surgical’s Q1 revenue hit $77 million, surpassing the expected $72 million. Evo implantable lens sales in the U.S. reached $5 million, exceeding projections. The stock price soared by 16.5%, indicating strong investor confidence. Staar sets a
Quick Look: Dell’s shares climbed 8.6%, marking a 67% rise in 2024 and 214% over the past year. Completed a historic $60 billion merger with EMC, expanding market footprint. Analysts rate the company as a ‘Moderate Buy,’ with a
Quick Look: Tesla (TSLA) faces its first annual sales decline amid fierce EV competition. Production at 433,000 vehicles; deliveries fell to 387,000 units. Price cuts strain profit margins, and TSLA’s stock drops sharply. Production issues include Model 3 updates
Quick Look: Micron’s stock hit a record high of $127.38, a 53% gain YTD, fueled by the AI sector growth. Bank of America raises the company’s price target to $144, citing potential in HBM chip technology. Analyst consensus rates
Asian stocks held to their nerve on Monday as data showed the Chinese economy slowed at the end of last year, emphasizing the urgent need for more stimulus as Beijing wrestles with the United States over trade. Investors are
Asian stocks inched up in subdued trade on Thursday after Wall Street ended higher, but political uncertainty in the United States and concerns about weakening global economic growth kept many investors on the sidelines. Financials spreadbetters expect London’s FTSE,
Investors sent Alphabet Inc.’s shares down about 3 percent after hours on Monday after the tech company reported a markedly higher fourth-quarter spending on video content, employees, and facilities. Google’s parent company beat Wall Street’s estimates for revenue and
Novartis AG prescription drug prices have been “flat to negative” over the last three years because of high costs for US patients on middlemen tasked to manage drug benefits, according to the company’s chief executive Vas Narasimhan. During an
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’ ratings from Citigroup and Stifel, and robust institutional support. Summit
Quick Look: Staar Surgical’s Q1 revenue hit $77 million, surpassing the expected $72 million. Evo implantable lens sales in the U.S. reached $5 million, exceeding projections. The stock price soared by 16.5%, indicating strong investor confidence. Staar sets a sales forecast of $335 million to $340 million for
Quick Look: Dell’s shares climbed 8.6%, marking a 67% rise in 2024 and 214% over the past year. Completed a historic $60 billion merger with EMC, expanding market footprint. Analysts rate the company as a ‘Moderate Buy,’ with a target price of around $102.88. In the whirlwind of
Quick Look: Tesla (TSLA) faces its first annual sales decline amid fierce EV competition. Production at 433,000 vehicles; deliveries fell to 387,000 units. Price cuts strain profit margins, and TSLA’s stock drops sharply. Production issues include Model 3 updates and factory disruptions. Recently Tesla has encountered its first
Quick Look: Micron’s stock hit a record high of $127.38, a 53% gain YTD, fueled by the AI sector growth. Bank of America raises the company’s price target to $144, citing potential in HBM chip technology. Analyst consensus rates Micron a ‘Strong Buy’, with an average price target
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported